Kevetrin had successfully demonstrated itself as extremely safe and effective in stopping, reversing, and at times curing lung, prostate, colon and breast cancer in animal trials. Recently it was announced that in in vitro studies Kevetrin has proven effective against brain cancer. So it's implied in Beth Israel's wedding of Kevetrin to Pfizer's already FDA-approved multikinase inhibitors, that Beth Israel's scientists believe that Kevetrin is not only very safe and extremely effective in animal trials against the major types of cancer but that it is probably an entirely new therapeutic platform having considerable oncolytic application to many, if not all forms of cancer. Indeed if Kevetrin can activate the P53 and P21 in the human genome without any toxic effects or damage to healthy tissue or cells, its therapeutic index might be as broad as the misery, morbidity, and grief index of cancer itself.

If Kevetrin's soon-to-be FDA human trails eclipse in humans that which it has accomplished in mice, we could be looking at an oncolytic therapeutic that either as a solo or part of a drug cocktail may be able to approach the revenue that Lipitor once commanded.